Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO INVESTORS REGULATORY PRESS RELEASES Regulatory Press Releases Regulatory information that Orexo is obliged to make public pursuant to the EU Market Abuse Regulation, Securities Market Act and the Financial Instruments Trading Act. Last 6 months 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Regulatory Pressrelease Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 16 November 2021 Orexo Press Release Orexo announces positive results from pivotal trial for its leading pharma project OX124_Nov 16 2021 Regulatory Interim Report Orexo Q3 2021 Interim Report 3 November 2021 Orexo Q3 2021 Interim Report published Regulatory Interim Report Orexo Q2 2021 Interim Report 15 July 2021 Orexo Interim Report Q2 2021 published July 15 Regulatory Interim Report Orexo Q1 2021 Interim Report 29 April 2021 Orexo Interim Report Q1 2021 published April 29 Regulatory Pressrelease Report from Orexo AB’s annual general meeting, 13 April 2021 13 April 2021 Report from Orexo AB’s annual general meeting Regulatory Report Orexo publishes Annual Report for 2020 23 March 2021 Orexo publishes Annual Report for 2020 Regulatory Pressrelease Orexo publishes prospectus and applies for admission to trading of corporate bonds 16 March 2021 Orexo publishes prospectus and applies for admission to trading of corporate bonds Regulatory Pressrelease Notice of Annual General Meeting of Orexo 10 March 2021 Notice of Annual General Meeting of Orexo Regulatory Pressrelease Orexo calls for redemption of its outstanding bonds and obtains temporary waiver 5 February 2021 Orexo calls for redemption of its outstanding bonds and obtains temporary waiver Regulatory Pressrelease Orexo has successfully issued senior unsecured callable floating rate bonds 4 February 2021 Orexo has successfully issued senior unsecured callable floating rate bonds Regulatory Pressrelease Orexo contemplates issue of senior unsecured callable floating rate bonds 1 February 2021 Orexo contemplates issue of senior unsecured callable floating rate bonds Regulatory Annual Financial Statement Orexo Q4 2020, incl. Full Year Report 28 January 2021 ZUBSOLV® stable and strong EBIT, despite challenging market due to Covid-19 Q4 2020, incl. Full Year Report Regulatory Pressrelease Correction notice of press release – Q3 2020 Interim Report – ZUBSOLV® guiding 2020 4 November 2020 Correction notice of press release – Q3 2020 Interim Report – ZUBSOLV® guiding 2020 Regulatory Interim Report Orexo Interim Report Q3 2020 4 November 2020 Orexo Interim Report Q3 2020 Regulatory Pressrelease Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US 10 August 2020 Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US Regulatory Interim Report Orexo Interim Report Q2 2020 16 July 2020 Orexo Interim Report Q2 2020 Regulatory Pressrelease Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance 2 July 2020 Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance Regulatory Pressrelease Number of shares and votes in Orexo 29 May 2020 Release Regulatory Pressrelease Report from Orexo AB’s extraordinary general meeting, 19 May 2020 19 May 2020 Release Regulatory Pressrelease Orexo acquires exclusive US rights to commercialize deprexis®, a world-leading digital therapy to help patients manage the symptoms of depression 11 May 2020 Orexo acquires exclusive US rights to commercialize deprexis® Regulatory Interim Report Interim Report Q1 2020 28 April 2020 Interim Report Q1 2020 Regulatory Pressrelease Notice of Extraordinary General Meeting of Orexo 16 April 2020 Release Regulatory Pressrelease Report from Orexo´s annual general meeting, 16 April 2020 16 April 2020 Report from Orexo´s annual general meeting, 16 April 2020 Regulatory Pressrelease Orexo ends share buy-back program 6 April 2020 Release Regulatory Report Orexo publishes the Annual Report for 2019 26 March 2020 Orexo publishes the Annual Report for 2019 Regulatory Pressrelease Notice of Annual General Meeting of Orexo 16 March 2020 Notice of Annual General Meeting of Orexo Regulatory Pressrelease Orexo AB (publ.) has resolved to carry out repurchases of own shares 17 February 2020 Orexo AB (publ.) has resolved to carry out repurchases of own shares Regulatory Annual Financial Statement Q4 incl. Full Year Report 2019 30 January 2020 Orexo Q4 incl. Full Year Report 2019 Regulatory Pressrelease Orexo acquires exclusive US rights to commercialize vorvida®, a digital therapy for alcohol use disorder with scientifically proven efficacy 27 November 2019 Orexo acquires exclusive US rights to commercialize vorvida®, a digital therapy for alcohol use disorder with scientifically proven efficacy Regulatory Interim Report Orexo Interim Report Q3 2019 24 October 2019 Orexo Q3 2019 Interim Report published Oct 24 Regulatory Interim Report Orexo Interim Report Q2 2019 11 July 2019 Orexo Q2 2019 Interim Report published July 11 2019 Regulatory Pressrelease Number of shares and votes in Orexo 28 June 2019 Number of shares and votes in Orexo Regulatory Pressrelease Issue and repurchase of class C shares 12 June 2019 Issue and repurchase of class C shares Regulatory Pressrelease Number of shares and votes in Orexo 31 May 2019 Number of shares and votes in Orexo Regulatory Interim Report Interim Report Q1 2019 2 May 2019 Orexo Interim Report Q1 2019 published May 2 2019 Regulatory Report Orexo publishes the Annual Report for 2018 21 March 2019 Orexo Annual Report 2018 Regulatory Pressrelease Notice of Annual General Meeting of Orexo 5 March 2019 Notice of Annual General Meeting of Orexo Regulatory Pressrelease Number of shares and votes in Orexo 28 February 2019 Number of shares and votes in Orexo Regulatory Annual Financial Statement Q4 incl. Full Year Report 2018 30 January 2019 Orexo Q4 incl. Full Year Report 2018 Regulatory Pressrelease Positive results from human PK study assessing Orexo’s new intranasal naloxone formulations for opioid overdose reversal 7 January 2019 Positive results from human PK study assessing Orexo’s new intranasal naloxone formulations Regulatory Pressrelease Orexo regains rights to Zubsolv® in all countries outside the US 13 December 2018 Orexo regains rights to Zubsolv® in all countries outside the US Regulatory Interim Report Interim Report Q3 2018 25 October 2018 Orexo Q3 2018 Interim Report announced October 25 2018 Regulatory Pressrelease Orexo appoints Joseph DeFeo as new CFO 24 October 2018 Orexo appoints Joseph DeFeo as new CFO Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2018/2019 8 October 2018 Orexo appoints Nomination Committee and publishes financial calendar 2018/2019 Regulatory Pressrelease Orexo wins appeal against Actavis on Zubsolv patent in the US 10 September 2018 Orexo wins appeal against Actavis on Zubsolv patent in the US Regulatory Interim Report Interim Report Q2 2018 11 July 2018 Orexo Interim Report Q2 2018 announced July 11 Regulatory Pressrelease Number of shares and votes in Orexo 29 June 2018 Orexo Press Release Number of Shares and Votes announced 29.6.2018 Regulatory Pressrelease Zubsolv® now launched in the EU, which triggers a EUR 3m milestone payment to Orexo 18 June 2018 Zubsolv® now launched in the EU, which triggers a EUR 3m milestone payment to Orexo Regulatory Pressrelease Issue and repurchase of class C shares 15 June 2018 Orexo Issue and repurchase of class C shares 15.6.2018 Regulatory Pressrelease Orexo´s CFO resigns and will leave the company in November 2018 31 May 2018 Orexo´s CFO resigns and will leave the company in November 2018 (PDF) Regulatory Interim Report Interim Report Q1 2018 26 April 2018 Release Regulatory Pressrelease Report from Orexo AB’s annual general meeting 12 April 2018 Release Regulatory Report Orexo publishes the Annual Report for 2017 22 March 2018 Annual Report 2017 Regulatory Pressrelease Notice of Annual General Meeting of Orexo 8 March 2018 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 January 2018 Release Regulatory Annual Financial Statement Full Year Report incl. Q4 2017 25 January 2018 Release Regulatory Pressrelease Orexo announces conditional total redemption of its senior unsecured bonds 27 October 2017 Release Regulatory Interim Report Orexo Interim Report Q3 2017 19 October 2017 Release Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2017/2018 3 October 2017 Release Regulatory Pressrelease Orexo signs asset purchase agreement with Gesynta Pharma AB for OX-MPI 2 October 2017 Release Regulatory Pressrelease CHMP positive opinion for opioid dependence treatment with Zubsolv® (buprenorphine and naloxone) in Europe 15 September 2017 Press release (PDF) Regulatory Interim Report Orexo Interim Report Q2 2017 11 July 2017 Release Regulatory Pressrelease Number of shares and votes in Orexo 30 June 2017 Release Regulatory Pressrelease Issue and repurchase of class C shares 16 June 2017 Release Regulatory Pressrelease Orexo receives USD 2.5 million milestone payment from AstraZeneca as OX-CLI advances into clinical trials 2 June 2017 Release Regulatory Interim Report Interim Report Q1 2017 20 April 2017 Release Regulatory Pressrelease Report from Orexo AB´s annual general meeting, April 6 2017 6 April 2017 Release Regulatory Report Orexo publishes the Annual Report for 2016 16 March 2017 Release Regulatory Pressrelease Notice of Annual General Meeting of Orexo 7 March 2017 Release Regulatory Pressrelease Orexo commences patent infringement litigation against Actavis for their generic versions of Suboxone® and Subutex® tablets in the US 1 March 2017 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 January 2017 Release Regulatory Annual Financial Statement Full Year Report 2016 26 January 2017 Release Regulatory Pressrelease Orexo appeal Zubsolv® US district court decision 8 December 2016 Release Regulatory Pressrelease Favorable outcome from Zubsolv® patent infringement litigation against Actavis 16 November 2016 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 October 2016 Release Regulatory Pressrelease Interim Report January-September 2016 20 October 2016 Release Regulatory Pressrelease FDA Approves Unique Low Dosage of Zubsolv® 6 October 2016 Release Regulatory Pressrelease Mundipharma and Orexo announce EU regulatory submission for Zubsolv® 4 October 2016 Release Regulatory Pressrelease Number of shares and votes in Orexo 30 September 2016 Release Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2016/2017 29 September 2016 Release Regulatory Pressrelease Issue and repurchase of class C shares 22 September 2016 Release Regulatory Pressrelease Interim Report January-June 2016 12 July 2016 Release Regulatory Pressrelease Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv® 30 June 2016 Release Regulatory Pressrelease Orexo sees very limited exposure to the UK and the British pound 21 June 2016 Release Regulatory Pressrelease Orexo to present at Jefferies 2016 Healthcare Conference, NYC 31 May 2016 Release Regulatory Pressrelease Interim Report January-March 2016 21 April 2016 Release Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, 15 April 2016 15 April 2016 Release Regulatory Pressrelease Orexo’s Annual Report for 2015 released 22 March 2016 Orexo Annual Report 2015 Orexo Press release Annual Report 2015 released 2016-03-22 Regulatory Pressrelease AstraZeneca acquires all rights to Orexo´s OX-CLI project 17 March 2016 Release Regulatory Pressrelease Notice of Annual General Meeting of Orexo 11 March 2016 Release Regulatory Pressrelease Number of shares and votes in Orexo 29 February 2016 Release Regulatory Annual Financial Statement Full year report January-December 2015 28 January 2016 Release Regulatory Pressrelease Orexo receives MGBP 5 milestone payment for Abstral® in Europe and records OX-MPI non-cash impairment charge of MSEK 62 11 December 2015 Release Regulatory Pressrelease New Abstral® partner in the US 20 November 2015 Release Regulatory Pressrelease Orexo Settles Abstral® US Patent Litigation with Actavis 27 October 2015 Release Regulatory Interim Report Interim report January-September 2015 22 October 2015 Release Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2015/2016 15 October 2015 Release Regulatory Pressrelease New regulations will expand access to treatment of opioid dependence in the US 18 September 2015 Release Regulatory Pressrelease Letter to Orexo shareholders from CEO Nikolaj Sørensen 2 September 2015 Release Regulatory Pressrelease Orexo’s Upcoming Presentations at Events during Second Half 2015 25 August 2015 Release Regulatory Pressrelease U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence 11 August 2015 Release Regulatory Pressrelease ZUBSOLV® Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid 4 August 2015 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 July 2015 Release Regulatory Interim Report Interim report January-June 2015 10 July 2015 Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. The full report Regulatory Pressrelease Number of shares and votes in Orexo 30 June 2015 Release Regulatory Pressrelease Orexo’s “Out the Monster” campaign wins a Gold Lions Health Award at the Cannes Lions Festival 25 June 2015 Release Regulatory Pressrelease Issue and repurchase of class C shares 17 June 2015 Release Regulatory Pressrelease FDA approves the medium tablet strength, 2.9 mg/0.71 mg, of ZUBSOLV® 10 June 2015 Release Regulatory Pressrelease Number of shares and votes in Orexo 29 May 2015 Release Regulatory Pressrelease Orexo divests subsidiary Kibion 30 April 2015 Release Regulatory Interim Report Interim report January-March 2015 23 April 2015 The full report Regulatory Pressrelease Orexo to present at 2015 Nordic Life Sciences Conference 22 April 2015 Release Regulatory Pressrelease New 24-week clinical study strengthens the evidence of the therapeutic value of Zubsolv® for maintenance treatment of opioid dependence 22 April 2015 Release Regulatory Pressrelease Report from Orexo AB’s annual general meeting, 15 April 2015 15 April 2015 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 March 2015 Release Regulatory Report Orexo’s annual report for 2014 released 25 March 2015 Orexo Annual Report 2014 Press release Regulatory Pressrelease Notice of Annual General Meeting of Orexo 16 March 2015 The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Wednesday 15 April 2015, at 4.00 pm in Orexo’s facilities at Virdings allé 32A, in Uppsala, Sweden. Notice of Annual General Meeting (PDF) Regulatory Pressrelease Orexo broadens ZUBSOLV® product range and announces newly listed granted US patent. 17 February 2015 Release Regulatory Pressrelease Orexo commences patent infringement litigation against Actavis concerning Abstral® in the US 5 February 2015 Release Regulatory Pressrelease Number of shares and votes in Orexo 30 January 2015 Release Regulatory Annual Financial Statement Full year report January-December 2014 29 January 2015 The full report Regulatory Pressrelease Orexo Receives Paragraph IV Notice Letter Concerning Abstral® in the US 15 January 2015 Release Regulatory Pressrelease Orexo receives million 5£ milestone payment for Abstral® in Europe and Zubsolv® continues strong market share growth in the US 17 December 2014 Release Regulatory Pressrelease FDA approves two higher dosage strengths of ZUBSOLV® 12 December 2014 Release Regulatory Pressrelease Number of shares and votes in Orexo 28 November 2014 Release Regulatory Interim Report Interim report January-September 2014 22 October 2014 The full report Regulatory Pressrelease Invitation - Presentation of Orexo's third quarter results 2014 15 October 2014 Press release (PDF) Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2014/2015 15 October 2014 Release Regulatory Pressrelease Orexo submits application to FDA for expanded label of ZUBSOLV® 13 October 2014 Release Regulatory Pressrelease Number of shares and votes in Orexo 30 September 2014 Release Regulatory Pressrelease Orexo has successfully completed its private placement of approx. SEK 346.5m 29 August 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF OREXO. Release Regulatory Pressrelease Orexo intends to conduct a private placement of shares to Swedish and international institutional and strategic investors 28 August 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF OREXO. Press release (PDF) Regulatory Pressrelease Orexo enhances commercial focus and operating efficiencies 20 August 2014 Press release (PDF) Regulatory Pressrelease OX-MPI project returned to Orexo 6 August 2014 Press release (PDF) Regulatory Pressrelease Number of shares and votes in Orexo 31 July 2014 Release Regulatory Pressrelease Correction to the Swedish Interim report January-June 2014 11 July 2014 Regulatory Interim Report Interim report January-June 2014 11 July 2014 Release Regulatory Pressrelease Orexo Added to Russell Global Index 30 June 2014 Release Regulatory Pressrelease Orexo commences patent infringement litigation against Actavis 27 June 2014 Release Regulatory Pressrelease Top-line data from a Phase 3 clinical trial demonstrates that Zubsolv® is as effective as Suboxone® film in the treatment of opioid dependence 25 June 2014 Release Regulatory Pressrelease Positive Top-line Results from Two Phase 3 Clinical Trials that Assessed Zubsolv® for Induction of Buprenorphine Maintenance Therapy 23 June 2014 Press release (PDF) Regulatory Pressrelease Orexo publishes bond prospectus and applies for listing of its bond loan on NASDAQ OMX Stockholm 9 June 2014 Release Regulatory Pressrelease Number of shares and votes in Orexo 30 May 2014 Release Regulatory Pressrelease Orexo announces new partner for the commercialization of Zubsolv® in the United States 20 May 2014 Release Regulatory Pressrelease Orexo has completed its SEK 500 million bond issue 12 May 2014 Release Regulatory Pressrelease Orexo issues a SEK 500 million bond loan on the Swedish bond market 30 April 2014 Press release (PDF) Regulatory Interim Report Interim report January-March 2014 25 April 2014 Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2013. The full report Regulatory Pressrelease Report from Orexo AB’s annual general meeting, 15 April 2014 15 April 2014 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 March 2014 Release Regulatory Report Orexo’s annual report for 2013 released 25 March 2014 Orexo Annual Report 2013 Press release Regulatory Pressrelease Notice of Annual General Meeting of Orexo 14 March 2014 The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Tuesday 15 April 2014, at 4.00 pm in Orexo’s facilities at Virdings allé 32A, in Uppsala, Sweden. PDF Regulatory Pressrelease Orexo Enters an Exclusive Reimbursement Agreement with UnitedHealth Group and OptumRx for ZUBSOLV® 12 March 2014 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 January 2014 Release Regulatory Annual Financial Statement Full year report January-December 2013 30 January 2014 The full report Regulatory Pressrelease Orexo adjusts EBIT expectations for Q4, 2013 20 December 2013 Release Regulatory Pressrelease Letter to Orexo shareholders from Chairman Martin Nicklasson 19 December 2013 Press release Letter to Shareholders Regulatory Pressrelease Orexo advances from Small to Mid Cap 19 December 2013 Press release (PDF) Regulatory Pressrelease Orexo announces the launch of Abstral® in Japan 12 December 2013 Release Regulatory Pressrelease Orexo announces a new MSEK 200 credit facility 12 December 2013 Release Regulatory Pressrelease Number of shares and votes in Orexo 29 November 2013 Release Regulatory Pressrelease Orexo AB ADRs commence trading on OTCQX in the U.S. 13 November 2013 PDF Regulatory Pressrelease Number of shares and votes in Orexo 31 October 2013 Release Regulatory Interim Report Interim report January-September 2013 23 October 2013 The full report Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2013/2014 15 October 2013 Release Regulatory Pressrelease Number of shares and votes in Orexo 30 September 2013 Release Regulatory Pressrelease Orexo announces the approval of Abstral® in Japan 20 September 2013 PDF Regulatory Pressrelease Orexo AB announces full implementation of its ADR Program in the United States concurrently with its commercial launch of Zubsolv® 16 September 2013 Press Release (PDF) Regulatory Pressrelease Orexo provides update on reimbursement and launch preparations for Zubsolv® 5 September 2013 Press Release (PDF) Regulatory Pressrelease Number of shares and votes in Orexo 30 August 2013 Release Regulatory Pressrelease Orexo reports successful completion of OX51 phase II dose-finding study in prevention of procedure-induced pain 28 August 2013 PDF Regulatory Pressrelease Orexo AB converts convertible bonds subscribed for by Novo A/S 26 August 2013 Release Regulatory Pressrelease First Patient Dosed in a New Clinical Study Designed to Assess Early Treatment Efficacy and Acceptability of Zubsolv® 7 August 2013 Release Regulatory Pressrelease First patient dosed in new study on long-term adherence to treatment of opioid dependence with Zubsolv® 7 August 2013 Release Regulatory Pressrelease Report from the extraordinary general meeting in Orexo AB, 6 August 2013 6 August 2013 PDF Regulatory Pressrelease Letter to shareholders from Chairman Martin Nicklasson 19 July 2013 PDF Letter to Shareholders July 2013 Regulatory Pressrelease Orexo appoints Henrik Juuel as new CFO 15 July 2013 Release Regulatory Interim Report Interim report January-June 2013 12 July 2013 Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2012. FDA approves Zubsolv™ for maintenance treatment of opioid dependence The full report Regulatory Pressrelease Notice of Extraordinary General Meeting of Orexo 4 July 2013 The shareholders in Orexo AB (publ) are summoned to the extraordinary general meeting, to be held on Tuesday 6 August 2013, at 4.00 pm in Orexos facilities at Virdings allé 32A, in Uppsala, Sweden. Notice of Extraordinary General Meeting (PDF) Regulatory Pressrelease FDA Approves Zubsolv™ for the Maintenance Treatment of Opioid Dependence 4 July 2013 pdf Regulatory Pressrelease Number of shares and votes in Orexo 2 July 2013 Release Regulatory Pressrelease Orexo Appoints Robert A. DeLuca as President of Orexo US Inc. 1 July 2013 PDF Regulatory Pressrelease Orexo Forms a Commercial Partnership with Publicis Touchpoint Solutions for launch of Zubsolv™ in the US 1 July 2013 Telephone conference today July 1 at 3:00 pm CET PDF Regulatory Pressrelease First patient dosed in new phase III study targeted towards a future clinical indication expansion for Zubsolv 17 June 2013 Press release (pdf) Regulatory Pressrelease Number of shares and votes in Orexo 31 May 2013 Release Regulatory Interim Report Interim report, January-March 2013 26 April 2013 Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2012. The full report Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, 11 April 2013 11 April 2013 Release Regulatory Pressrelease Number of shares and votes in Orexo 28 March 2013 Release Regulatory Report Orexo’s annual report for 2012 released 21 March 2013 Orexo Annual Report 2012 Press release Regulatory Pressrelease Orexo sells Abstral® in the United States to Galena Biopharma, Inc. 18 March 2013 Telephone conference March 18 at 1:00pm CET Release Regulatory Pressrelease Notice of Annual General Meeting of Orexo 12 March 2013 The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Thursday 11 April 2013, at 5.00 pm in Orexo’s facilities at Virdings allé 32A, in Uppsala, Sweden. PDF Regulatory Pressrelease Number of shares and votes in Orexo 28 February 2013 Release Regulatory Pressrelease Agreement with Novartis on OX17 for GERD terminated 25 February 2013 Release Regulatory Pressrelease Orexo strengthens the commercial leadership structure and appoints Nikolaj Sørensen as new CEO and Martin Nicklasson as Executive Chairman 5 February 2013 Release Regulatory Pressrelease Number of shares and votes in Orexo 31 January 2013 Release Regulatory Annual Financial Statement Interim report, January-December 2012 31 January 2013 OREXO IS PREPARING ZUBSOLV™ FOR LAUNCH IN THE USA - DRUG APPLICATION ACCEPTED BY FDA WITH A JULY 6, 2013 TARGET APPROVAL DATE The full report Regulatory Pressrelease Orexo enters research agreement with AstraZeneca for respiratory disease program 25 January 2013 Release Regulatory Pressrelease Number of shares and votes in Orexo 28 December 2012 Release Regulatory Pressrelease Orexo provides US commercialization progress update and direction for 2013 financial outlook 19 December 2012 Orexo AB (Orexo) today informs about the progress towards becoming a full-fledged specialty pharmaceutical company with a US commercial presence. Orexo also announced the company project it will turn profitable in late 2013, with the current assumptions on regulatory timing and launch of Zubsolv™ in September 2013. Zubsolv™ and Abstral® to be commercialized in partnership Release Regulatory Pressrelease Number of shares and votes in Orexo 30 November 2012 Release Regulatory Pressrelease New study by Orexo emphasizes importance of Zubsolv™ product characteristics in direct comparison to Suboxone® Film 28 November 2012 Orexo AB (Orexo) today announced the successful completion of an acceptability study comparing Zubsolv (OX219) to Suboxone Film, which is the leading product for treatment of opioid dependence. The study shows that 9 out of 10 participants would choose Zubsolv over Suboxone Film for a daily treatment. Release Regulatory Pressrelease Orexo announces that Zubsolv™ has been accepted for review by the U.S. Food and Drug Administration (FDA) 19 November 2012 FDA has informed Orexo that the Zubsolv New Drug Application (NDA) has been accepted for review, and that the Prescription Drug User Fee Act (PDUFA) action date will be July 6, 2013. Release Regulatory Pressrelease Orexo announces submission of a New Drug Application for KW‑2246 (Abstral®) in Japan 13 November 2012 Swedish specialty pharmaceutical company Orexo today communicated that its partner Kyowa Hakko Kirin Co., Ltd has submitted a New Drug Application (“NDA”) in Japan for KW-2246 (Abstral), a fentanyl sublingual tablet developed for the treatment of breakthrough cancer pain. PDF Regulatory Pressrelease Number of shares and votes in Orexo 31 October 2012 Release Regulatory Pressrelease Orexo announces dosing of first patient with OX51 in phase II clinical trial on prevention of procedure-induced pain 30 October 2012 Swedish specialty pharmaceutical company Orexo today communicated the start of the dose finding study for OX51 in patients undergoing prostate biopsy. Results from the study, which is a European study enrolling approximately 200 patients, will be available during the first half of 2013. PDF Regulatory Interim Report Interim report, January-September 2012 25 October 2012 OREXO CLOSER TO LAUNCHING ZUBSOLV™ (OX219) – NEW TREATMENT OF OPIOID DEPENDENCE Release Regulatory Pressrelease Orexo appoints Nomination Committee and publishes financial calendar 2012/2013 11 October 2012 Release Regulatory Pressrelease Orexo announces decision to explore strategic alternatives for commercialization in the US 4 October 2012 Release Regulatory Pressrelease Number of shares and votes in Orexo 28 September 2012 Release Regulatory Pressrelease Orexo provides update on simplified market situation for Zubsolv™ (OX219) in United States 25 September 2012 PDF Regulatory Pressrelease Orexo presents an update on the US opioid dependence market, and the commercial opportunities for Zubsolv™ (OX219) 21 September 2012 PDF Regulatory Pressrelease Orexo halts share buyback due to upcoming Q3 interim report 21 September 2012 Release Regulatory Pressrelease Orexo invites to a Zubsolv™ (OX219) information meeting on September 21 in Stockholm 17 September 2012 Release Regulatory Pressrelease Swedish specialty pharmaceutical company Orexo announced today the submission of a New Drug Application for Zubsolv™ (OX219) to the US FDA 6 September 2012 Orexo is the first company to submit a New Drug Application (NDA) for a novel combination product of buprenorphine and naloxone for treatment of opioid dependence, a condition affecting over two million Americans. PDF Regulatory Pressrelease Orexo reports successful achievement of product stability data for OX219 – submission of the US file now advanced 5 months to September 2012 21 August 2012 Swedish specialty pharmaceutical company Orexo today communicated that it projects a late Q3 regulatory submission to the US regulatory agency FDA of its treatment of opioid dependence, OX219. Opioid dependence is in the US increasingly being recognized as a major health problem, with over two million Americans affected and costing the society an estimated USD 25 billion in related health care cost. Release Regulatory Pressrelease Orexo reports positive feedback from pre-NDA meeting with FDA – clearing path for regulatory submission of OX219 23 July 2012 A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219. PDF Regulatory Pressrelease Buyback of company shares 16 July 2012 Release Regulatory Pressrelease Report from the extraordinary general meeting in Orexo AB, 13 July 2012 13 July 2012 Release Regulatory Interim Report Interim report, January-June 2012 12 July 2012 STRONG REVENUE GROWTH AND CASH FLOW. ALL CLINICAL STUDIES FOR KEY PROJECT OX219 COMPLETED AHEAD OF PLAN. The full report Regulatory Pressrelease Orexo takes large step forward on the road to improve treatment for people dependent on opioid pain killers 2 July 2012 Release Regulatory Pressrelease Number of shares and votes in Orexo 29 June 2012 Release Regulatory Pressrelease Orexo successfully completes OX219 dose proportionality study ahead of schedule 19 June 2012 PDF Regulatory Pressrelease Orexo reports regulatory approval of Edluar® in Europe 18 June 2012 PDF Regulatory Pressrelease Notice of Extraordinary General Meeting of Orexo 14 June 2012 The shareholders in Orexo AB (publ) are summoned to the extraordinary general meeting, to be held on Friday 13 July 2012, at 3.00 pm in Orexos facilities at Virdings allé 32A, in Uppsala, Sweden. PDF Regulatory Pressrelease Orexo plans buyback program of company shares 14 June 2012 PDF Regulatory Pressrelease Orexo acquires all US rights for Abstral and receives a net cash consideration of MSEK 610 4 June 2012 Telephone conference today June 4 at 10:00am CET Press release - Orexo acquires all US rights for Abstral and receives a net cash consideration of MSEK 610 Regulatory Pressrelease Orexo acquires US commercial rights of Abstral and ProStrakan acquires the corresponding rights in the EU and rest of the world 4 June 2012 Press release - Orexo acquires US commercial rights of Abstral and ProStrakan acquires the corresponding rights in the EU and rest of the world Regulatory Pressrelease Abstral EU success continues. Orexo receives sales milestone of 3.3 MEUR. 25 May 2012 Press release - Orexo receives sales milestone of 3.3 MEUR. Regulatory Pressrelease Orexo presents new focus and plans for commercial expansion – accelerated development of OX219 3 May 2012 Release Regulatory Interim Report Interim report, January-March 2012 27 April 2012 Release Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, 11 April 2012 11 April 2012 Release Regulatory Pressrelease Notice of Annual General Meeting of Orexo 12 March 2012 The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Wednesday 11 April 2012, at 4.00 pm in Orexos facilities at Virdings allé 32A, in Uppsala, Sweden. wkr0001.pdf Regulatory Pressrelease Orexo AB focuses its business and reduces costs 6 March 2012 wkr0001.pdf Regulatory Annual Financial Statement Interim Report January-December 2011 31 January 2012 wkr0001.pdf Regulatory Pressrelease Orexo’s drug discovery collaboration terminated and OX-CLI/OX-ESI projects end 31 January 2012 wkr0001.pdf Regulatory Pressrelease Positive study results for OX27 20 December 2011 wkr0001.pdf Regulatory Pressrelease Orexo and Uppsala University receive Swedish Research Council grant for bioceramics project 30 November 2011 Uppsala, November 30 2011 - Orexo AB (STO: ORX) has been awarded a 2.1 million SEK grant from the Swedish Research Council for the project "Bioceramic materials for slow release of potent drugs". The project will be conducted between 2012 and 2015 in collaboration with a research team, led by Professor Håkan Engqvist, Applied Materials Science, Department of Engineering Sciences at Uppsala University. wkr0005.pdf Regulatory Interim Report Interim report, January-September 2011 9 November 2011 Uppsala, November 9, 2011 - Orexo´s proprietary development programs advance wkr0005.pdf Regulatory Pressrelease Nomination Committee prior to Orexo’s Annual General Meeting 2012 and Financial calendar 2011/2012 11 October 2011 wkr0005.pdf Regulatory Pressrelease Orexo appoints Peter Edman as Chief Scientific Officer 4 October 2011 wkr0001.pdf Regulatory Pressrelease Orexo announces positive results supporting OX219 for treatment of opioid dependence 21 September 2011 wkr0001.pdf Regulatory Pressrelease Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen as Chief Commercial Officer 16 September 2011 wkr0001.pdf Regulatory Pressrelease Orexo appoints Carl-Johan Blomberg as new Chief Financial Officer 31 August 2011 wkr0001.pdf Regulatory Interim Report Interim report January-June 2011 10 August 2011 STRONG SALES INCREASE FOR ABSTRAL® References made in this interim report relate to the Group unless otherwise stated. Figures in parentheses relate to the corresponding period in 2010. wkr0001.pdf Regulatory Pressrelease Changes in ownership in Orexo AB – new number of shares and votes 29 July 2011 wkr0001.pdf Regulatory Pressrelease Sublinox (Edluar) approved in Canada 25 July 2011 wkr0001.pdf Regulatory Pressrelease Orexo takes leading position in diagnostic breath tests through acquisition 14 July 2011 Uppsala, July 14, 2011 – Orexo AB (STO: ORX) has, through its subsidiary Kibion AB, acquired the German company Wagner Analysen Technik GmbH (WAT). WAT is a leading manufacturer of IRIS instruments and substrates for diagnostic breath tests. The acquisition turns Kibion into a complete solutions provider of both diagnostic breath tests and instruments, with a leading position in Helicobacter pylori tests. wkr0005.pdf Regulatory Pressrelease Orexo announces successful completion of rights issue providing gross proceeds of about SEK 250 million 29 June 2011 wkr0001.pdf Regulatory Pressrelease Orexo announces addendum to prospectus made public 15 June 2011 wkr0001.pdf Regulatory Pressrelease Abstral® launches in Canada 14 June 2011 Uppsala, Sweden, June 14 2011 – Through its local partner, Orexo now initiates marketing and sales of the pain treatment Abstral in Canada. wkr0001.pdf Regulatory Pressrelease Orexo announces successful completion of the first clinical trial with OX27 14 June 2011 wkr0001.pdf Regulatory Pressrelease Orexo announces prospectus regarding rights offering 30 May 2011 Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia. wkr0005.pdf Regulatory Pressrelease Report from Orexo AB’s extraordinary shareholders’ meeting, 27 May 2011 27 May 2011 Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia. wkr0005.pdf Regulatory Pressrelease Notice of Extraordinary General Meeting in Orexo 4 May 2011 wkr0001.pdf Regulatory Pressrelease Orexo launches underwritten rights issue of MSEK 250 4 May 2011 Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia. wkr0001.pdf Regulatory Interim Report Interim report, January-March 2011 4 May 2011 References made in this interim report relate to the Group unless otherwise stated. Figures in parentheses relate to the same period in the previous year. wkr0001.pdf Regulatory Pressrelease Orexo AB announces that Robin Wright resigns as CFO 11 April 2011 wkr0005.pdf Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, 7 April 2011 7 April 2011 wkr0005.pdf Regulatory Pressrelease Abstral® launched and now available in the United States 4 April 2011 wkr0005.pdf Regulatory Pressrelease Orexo announces successful completion of the first clinical trial in OX51 31 March 2011 wkr0005.pdf Regulatory Pressrelease Notice of Annual General Meeting of Orexo 8 March 2011 The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Thursday 7 April 2011, at 3.00 pm at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden. wkr0005.pdf Regulatory Pressrelease Abstral® approved in Canada 22 February 2011 wkr0005.pdf Regulatory Pressrelease Report from Orexo AB’s extraordinary shareholders’ meeting, 16 February 2011 17 February 2011 wkr0005.pdf wkr0006.pdf Regulatory Annual Financial Statement Orexo AB (publ.) - Year-end Report, January to December 2010 16 February 2011 Uppsala, February 16, 2011 - Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase. wkr0005.pdf Regulatory Pressrelease Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific 14 January 2011 Alliance to Include Commercialization in 11 countries, including Australia and India wkr0005.pdf Regulatory Pressrelease Anders Lundström to be the new CEO of Orexo 13 January 2011 Uppsala, January 13, 2011 - Orexo AB (STO: ORX) announces today that Anders Lundström has been appointed as its new CEO, to lead the company through its commercial development. He comes from Biogen Idec in the US, one of the world’s most successful biotech companies. wkr0005.pdf Regulatory Pressrelease Notice of Extraordinary General Meeting of Orexo AB, February 16, 2011 11 January 2011 wkr0001.pdf wkr0002.pdf wkr0003.pdf Regulatory Pressrelease FDA Approval for Abstral (Fentanyl) Sublingual Tablets - US launch planned for Q1 2011 10 January 2011 wkr0005.pdf Regulatory Pressrelease Orexo and Boehringer Ingelheim report progress in their pain and inflammatory diseases collaboration 16 December 2010 wkr0005.pdf Regulatory Pressrelease Orexo reports phase I trial results for OX219, a novel sublingual tablet formulation for the treatment of opioid dependence 14 December 2010 wkr0005.pdf Regulatory Pressrelease Orexo announces new sales figures for Abstral™ from its partner ProStrakan and updates on the US approval 16 November 2010 wkr0005.pdf Regulatory Interim Report Orexo AB (publ.) – Interim report, January-September 2010 10 November 2010 Uppsala, November 10, 2010 - Abstral™ for treatment of breakthrough cancer pain continued to grow strongly wkr0001.pdf Regulatory Pressrelease Orexo strengthens its subsidiary Kibion by recruiting Petter Bäckgren as CEO 27 October 2010 wkr0005.pdf Regulatory Pressrelease Nomination Committee prior to Orexo’s Annual General Meeting 2011 and Financial calendar 2010/2011 22 October 2010 wkr0001.pdf Regulatory Pressrelease Orexo signs agreement for Abstral™ for the Middle East and Africa 16 September 2010 wkr0001.pdf Regulatory Pressrelease Update on the FDA review for Abstral™ 7 September 2010 wkr0005.pdf Regulatory Pressrelease Orexo announces that partner Kyowa Hakko Kirin is to conduct additional clinical trials on KW-2246 for treatment of cancer pain in Japan 27 August 2010 wkr0005.pdf Regulatory Pressrelease Orexo notes significant change in its owner structure 26 August 2010 wkr0005.pdf Regulatory Interim Report Orexo AB (publ.) – Interim report, January-June 2010 20 August 2010 wkr0005.pdf Regulatory Pressrelease Orexo launches next step in strategy, new development programs and announces change of CEO 20 August 2010 wkr0005.pdf Regulatory Pressrelease Orexo appoints Robin Wright as new EVP Head of Finance and Strategy 10 August 2010 wkr0005.pdf Regulatory Pressrelease Orexo confirms Abstral PDUFA date update 2 June 2010 wkr0005.pdf Regulatory Pressrelease Orexo enters into an alliance and license agreement for new drugs to treat respiratory diseases 1 June 2010 wkr0005.pdf Regulatory Pressrelease Orexo reports continued strong AbstralTM sales in Europe 18 May 2010 wkr0011.pdf Regulatory Pressrelease Orexo to present at Rodman & Renshaw 6th Annual Global Healthcare Conference 7 May 2010 wkr0011.pdf Regulatory Interim Report Orexo AB (publ) – Interim report, January-March 2010 5 May 2010 wkr0011.pdf Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, April 21, 2010 21 April 2010 wkr0011.pdf Regulatory Pressrelease Novo transaction completed 7 April 2010 wkr0011.pdf Regulatory Pressrelease Report from the extraordinary general meeting in Orexo AB (publ), 31 March 2010 31 March 2010 wkr0011.pdf Regulatory Pressrelease Notice of Annual General Meeting in Orexo AB 23 March 2010 The shareholders in Orexo AB (publ) are summoned to the annual general meeting (the “Meeting”), to be held on Wednesday 21 April 2010, at 3.00 pm at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden. wkr0011.pdf Regulatory Pressrelease Orexo Strengthens Financial and Strategic Position with Placement of Convertible Bonds and Existing Shares to the Growth Equity unit of Novo A/S 15 March 2010 wkr0011.pdf Regulatory Pressrelease Notice of Extraordinary General Meeting 15 March 2010 The shareholders in Orexo AB (publ) are summoned to an extraordinary general meeting to be held on Wednesday 31 March 2010, at 10.00 am at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden. wkr0011.pdf Regulatory Pressrelease Orexo announces Kyowa Hakko Kirin’s submission of KW-2246 (Abstral) for approval in Japan 25 February 2010 wkr0011.pdf Regulatory Annual Financial Statement Orexo AB (publ.) – Year-end Report January-December 2009 17 February 2010 wkr0011.pdf Regulatory Pressrelease Orexo confirms Canadian Regulatory Filing of Abstral 4 February 2010 wkr0011.pdf Regulatory Pressrelease Orexo announces that partner Kyowa Hakko Kirin entered a Joint Distribution Agreement on KW-2246 for treatment of cancer pain in Japan 2 February 2010 wkr0011.pdf Regulatory Pressrelease Orexo announces that partner ProStrakan has presented strong sales figures for Abstral in Europe 7 January 2010 wkr0011.pdf Regulatory Interim Report Orexo AB (publ) – Interim report January-September 2009 10 November 2009 wkr0011.pdf Regulatory Pressrelease Nomination Committee prior to Orexo’s 2010 Annual General Meeting 16 October 2009 wkr0011.pdf Regulatory Pressrelease Orexo confirms FDA acceptance of Abstral filing 6 October 2009 wkr0011.pdf Regulatory Pressrelease New number of shares and votes in Orexo AB (publ) 31 August 2009 wkr0011.pdf Regulatory Pressrelease Orexo signs exclusive worldwide license agreement for a novel formulation 28 August 2009 wkr0011.pdf Regulatory Interim Report Orexo AB (publ) – Interim report, January - June 2009 21 August 2009 wkr0011.pdf Regulatory Pressrelease Orexo announces that its partner Meda has initiated the launch of EdluarTM in the USA 18 August 2009 wkr0011.pdf Regulatory Pressrelease Abstral™ file submitted to the FDA for approval in the USA 6 August 2009 wkr0011.pdf Regulatory Pressrelease Orexo announces positive Phase III results for KW-2246 in Japan 24 July 2009 wkr0011.pdf Regulatory Pressrelease Orexo announces that Abstral is ready for launch in France 30 June 2009 wkr0011.pdf Regulatory Interim Report Orexo AB (publ.) – Interim report, January-March 2009 6 May 2009 wkr0003.pdf Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, 23 April 2009 23 April 2009 wkr0003.pdf Regulatory Report Orexo’s annual report for 2008 released 6 April 2009 wkr0003.pdf wkr0010.pdf Regulatory Pressrelease Notice of Annual General Meeting of Orexo AB, 23 April 2009 25 March 2009 wkr0003.pdf wkr0010.pdf wkr0011.pdf Regulatory Pressrelease Orexo announces Phase IIa data on OX914 in rhinitis 24 March 2009 wkr0003.pdf Regulatory Pressrelease Orexo’s Edluar (Sublinox) receives FDA approval for the treatment of insomnia 16 March 2009 wkr0003.pdf Regulatory Pressrelease Orexo’s AbstralTM receives two further large EU market approvals in France and Spain 2 March 2009 wkr0003.pdf Regulatory Pressrelease New number of shares and votes in Orexo AB (publ) 27 February 2009 wkr0003.pdf Regulatory Pressrelease Orexo acquires a UK drug delivery company 23 February 2009 wkr0003.pdf Regulatory Pressrelease Orexo signs agreement for Abstral in Israel 18 February 2009 wkr0003.pdf Regulatory Annual Financial Statement Orexo AB (publ) – Year-end Report January–December, 2008 17 February 2009 wkr0003.pdf Regulatory Pressrelease Orexo signs an exclusive development agreement for its OX17 program 9 February 2009 wkr0003.pdf Regulatory Pressrelease Orexo signs agreement for Abstral in China 27 January 2009 wkr0003.pdf Regulatory Pressrelease Abstral receives marketing approval in Germany 11 December 2008 wkr0003.pdf Regulatory Interim Report Orexo AB (publ) – Interim report January-September 2008 10 November 2008 wkr0003.pdf Regulatory Pressrelease Orexo and ProStrakan advance date for taking over rights for Rapinyl in North America 31 October 2008 wkr0003.pdf Regulatory Pressrelease Nomination Committee prior to Orexo’s 2009 Annual General Meeting 23 October 2008 wkr0003.pdf Regulatory Pressrelease UK Marketing Approval Issued for Abstral 23 September 2008 Orexo AB (OMX: ORX) confirms the announcement made by ProStrakan Group plc (LSE: PSK), Orexo's partner for Abstral® in Europe and North America, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Marketing Authorisation for Abstral (for breakthrough cancer pain). As a result of the approval, Orexo will receive a milestone payment of USD 1 million. wkr0003.pdf Regulatory Pressrelease Orexo and Boehringer Ingelheim extend their research collaboration 8 September 2008 Uppsala, Sweden, September 8, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company and Boehringer Ingelheim, the international pharmaceutical company headquartered in Ingelheim, Germany, have extended their existing three year research collaboration for a further 12 months from November 2008. The research collaboration is a part of an exclusive world-wide license to develop and market a new class of drugs with a novel mechanism of action for the treatment of pain and inflammation. wkr0003.pdf Regulatory Pressrelease Orexo initiates clinical phase II program for OX914 - a new product candidate for the treatment of inflammatory airway diseases 2 September 2008 Uppsala, Sweden, September 2, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announced today that the phase II program for the product OX914 has started. This is a new product candidate for the treatment of inflammatory airway diseases including asthma, COPD (chronic obstructive pulmonary disease) and rhinitis. wkr0003.pdf Regulatory Interim Report Interim report January-June 2008 14 August 2008 wkr0003.pdf Regulatory Pressrelease Correction to the press release regarding sales milestone payments in Europe in connection with the new Licensing Agreement with ProStrakan 1 August 2008 The potential sales milestone payments in Europe in connection with the new agreement with ProStrakan amount to 19.9 MEUR and not 29.9 MEUR as announced in the previous press release from today. wkr0003.pdf Regulatory Pressrelease New sales milestone payments in Europe in connection with the new Licensing Agreement with ProStrakan 1 August 2008 This is a complement to the press release from yesterday. In connection with the new agreement with ProStrakan, apart from higher royalty rates, the potential sales milestone payments in Europe have increased from 10.0 MEUR to 29.9 MEUR. wkr0003.pdf Regulatory Pressrelease Orexo and ProStrakan Extend Licensing Agreement for Rapinyl/Abstral and change Partner in North America 31 July 2008 Uppsala, Sweden, 31 July, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company, and ProStrakan Group plc, the Scottish-based international specialty pharmaceutical company, have extended their existing European licensing agreement for Rapinyl™ (Abstral®), for breakthrough cancer pain, to include North America. This change of partner in North America follows the decision made by Endo Pharmaceuticals Holdings Inc. today following its own internal strategy changes to return all rights for Rapinyl™ (Abstral®) to Orexo. Endo has invested approximately $40 million in the development of Rapinyl™, and Orexo has received an additional $26.9 million in licensing payments. Endo will finalize and finance the current phase III studies of Rapinyl™ expected to end in December 2008. wkr0003.pdf Regulatory Pressrelease The FDA has accepted for filing the registration application for Sublinox™ 29 July 2008 The submitted registration application for SublinoxTM (OX22) has been accepted by the FDA as complete for substantive review after initial evaluation. SublinoxTM contains the well-known active substance zolpidem and is based on Orexo’s sublingual technology, involving a rapidly disintegrating tablet placed under the tongue. wkr0003.pdf Regulatory Pressrelease Orexo report Abstral (Rapinyl) approval in Europe 26 June 2008 Uppsala, Sweden, 26 June, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain. ProStrakan Group plc, the international speciality pharmaceutical is Orexo´s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe. Abstral/Rapinyl will be launched in Sweden in Q3 2008 and, as a result of today’s announcement, across Europe from the end of 2008 under the brand name Abstral. wkr0003.pdf Regulatory Pressrelease Orexo strengthens the Executive Management Group 9 June 2008 Orexo recruits Robin Wright, with extensive experience from international corporate finance and business development in the pharmaceutical and life science sector, as responsible for Business & Commercial Development. Robin Wright will be part of Orexo’s Executive Management Group. wkr0003.pdf Regulatory Pressrelease Orexo has submitted the registration application (NDA) for Sublinox™ (OX22) to the FDA on May 14 2008 15 May 2008 Sublinox™ (OX22), for treatment of short term insomnia, contains the well-documented substance zolpidem, and is based on Orexo’s sublingual technology involving a tablet placed under the tongue. wkr0003.pdf Regulatory Pressrelease Orexo to present at Rodman & Renshaw 5th Annual Global Healthcare Conference 12 May 2008 wkr0003.pdf Regulatory Pressrelease Orexo to present at BioEquity Europe 2008 12 May 2008 wkr0003.pdf Regulatory Interim Report Interim Report January-March 2008 7 May 2008 Executing in line with the strategy to build a profitable company wkr0003.pdf Regulatory Pressrelease Orexo reports positive results from phase I study for OX19 29 April 2008 Data from a phase I study confirms that Orexo’s new nasal spray formula for the administration of the desmopressin peptide for incontinence, shows significantly better uptake than nasal sprays currently on the market. Next step for Orexo is to seek partnership for further development of the product. wkr0003.pdf Regulatory Pressrelease Orexo and Meda in a potential billion SEK deal 14 April 2008 Meda has acquired the exclusive world-wide commercialization rights from Orexo of two patented drugs in late development phase; Sublinox and OX-NLA. wkr0003.pdf Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, April 3, 2008 3 April 2008 wkr0003.pdf Regulatory Pressrelease Orexo announces results confirming the clinical profile of OX17 in reflux disease (GERD) 27 March 2008 New clinical data from a phase II study confirms the competitive profile of Orexo’s product OX17 in GERD patients, i.e. fast, effective and sustained inhibition of gastric acid production, a prerequisite for effective symptom relief in the patient. The result demonstrates the clinical potential of OX17 and is an important step in the development of a competitive product. wkr0003.pdf Regulatory Pressrelease Orexo’s product NLA Nasal Spray shows excellent local tolerability in patients with rhinitis 18 March 2008 wkr0003.pdf Regulatory Pressrelease Rapinyl™ has received Swedish Marketing Authorization 7 March 2008 Uppsala, Sweden, 7th March 2008 - Orexo´s licensing partner for Rapinyl™ in Europe, ProStrakan Group plc announces that Rapinyl™ has received Swedish Marketing Authorization. It is anticipated that the product branded as “Abstral” will be launched in Sweden in Q3 2008 through Orexo´s joint venture with ProStrakan, which operates in the Nordic countries. wkr0003.pdf Regulatory Pressrelease Notice of Annual General Meeting in Orexo AB 4 March 2008 wkr0003.pdf Regulatory Annual Financial Statement Year-end Report January - December 2007 15 February 2008 wkr0003.pdf Regulatory Pressrelease Orexo AB – Financial calendar 2008 15 January 2008 wkr0003.pdf Regulatory Pressrelease Orexo discloses new mechanism for asthma and COPD treatment 10 January 2008 The discovery of the eoxins and their characteristics has paved the way for a new class of pharmaceuticals for treatment of asthma and COPD. One of the world's most-cited scientific journals, Proceedings of the National Academy of Sciences of the United States (PNAS), is now publishing Orexo’s research on the initial discovery and biological functions of eoxins. The publication describes the scientific rationale behind Orexo’s drug development program on eoxin inhibitors. wkr0003.pdf Regulatory Pressrelease Orexo´s partner Endo announces positive results from interim analysis of Rapinyl ™ phase III clinical trial 17 December 2007 wkr0003.pdf Regulatory Pressrelease Changed number of shares and votes in Orexo AB 30 November 2007 wkr0021.pdf Regulatory Pressrelease Orexo announces new Executive Management Team 26 November 2007 Following the completion of the Biolipox acquisition, Orexo has appointed a new Executive Management Team. The new Executive Management Team consists of Torbjörn Bjerke (President & CEO), Claes Wenthzel (Executive Vice President & CFO), Thomas Lundqvist (Executive Vice President och Executive Advisor), Göran Smedegård (Vice President Business Development & Commercial Development) and Göran Tornling (Executive Vice President R&D). wkr0021.pdf Regulatory Pressrelease Orexo completes the acquisition of Biolipox, appoints new CEO and publishes a prospectus 23 November 2007 Orexo AB has today completed the previously announced acquisition of Biolipox AB. Orexo has acquired all shares and warrants in Biolipox through payment consisting of 7.630.895 new shares in Orexo and 926.000 warrants entitling to subscription for 926.000 new shares in Orexo. wkr0088.pdf Regulatory Pressrelease The board of directors of Orexo resolves to issue new shares with payment in kind 21 November 2007 Due to Orexo AB’s acquisition of Biolipox AB, the board of directors of Orexo has today resolved, in accordance with the authorization from the extraordinary shareholders’ meeting held on November 13, 2007, to issue not more than 7,630,895 new shares and not more than 926,000 warrants entitling to subscription for not more than 926,000 new shares in Orexo, whereby the company’s share capital may be increased by not more than SEK 3,422,758. wkr0020.pdf Regulatory Pressrelease Biolipox completes aquisition from Inflazyme 20 November 2007 wkr0026.pdf Regulatory Pressrelease Report from Orexo AB’s Extraordinary Shareholders’ Meeting 13 November 2007 wkr0011.pdf Regulatory Pressrelease Orexo acquires Biolipox – Update regarding revised transaction structure and proposal regarding election of chairman and members of the board of directors for the Extraordinary General Meeting on November 13, 2007 12 November 2007 As previously announced in a press release on October 15, 2007, Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement according to which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). wkr0035.pdf Regulatory Pressrelease Nomination Committee for Orexo’s Annual General Meeting 2008 5 November 2007 wkr0031.pdf Regulatory Pressrelease Endo announces update on Phase III-program for Orexo´s pain product Rapinyl™ 1 November 2007 wkr0018.pdf Regulatory Pressrelease Notice of Extraordinary Shareholders’ Meeting in Orexo AB 30 October 2007 wkr0001.pdf Regulatory Pressrelease Orexo to acquire Biolipox - Update 26 October 2007 As previously announced in a press release on October 15, 2007 Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). wkr0011.pdf wkr0074.pdf Regulatory Pressrelease Orexo signs distribution agreement with Hospira in Asia for pain product Rapinyl™ 25 October 2007 Orexo AB and the specialty pharmaceuticals and medication delivery company Hospira have signed a distribution agreement that grants Hospira exclusive rights to market and sell Rapinyl™, Orexo’s patented product for treatment of break-through pain in cancer, in Asia Pacific markets including Australia and New Zealand. Market rights for the US, the EU and Japan were previously out-licensed, while another distribution agreement has also been signed for the CIS, Bulgaria and Romania. wkr0011.pdf Regulatory Interim Report Interim Report January - September 2007 23 October 2007 wkr0077.pdf Regulatory Pressrelease Changed date for the Q3 2007 report 18 October 2007 wkr0001.pdf Regulatory Pressrelease Notice of Extraordinary Shareholders’ Meeting in Orexo AB 16 October 2007 wkr0028.pdf Regulatory Pressrelease Orexo to acquire Biolipox - building a specialty pharma company driven by innovation 15 October 2007 Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The acquisition will create an innovative specialty pharma company with a broad product pipeline, global partnerships with major financial potential, and established sales channels. Substantial shareholder value will be created through operational synergies and by optimizing the potential of the combined product pipeline. The transaction will take place through an issue in kind to Biolipox's shareholders. The deal values Biolipox at SEK 856 million, and payment will be made through an issue of a maximum of 8,560,000 Orexo shares. The final structure of the transaction is dependent on Orexo's completion of due diligence of Biolipox. The deal is also conditional upon approval of the issue in kind by an extraordinary general meeting of Orexo and customary regulatory approvals. A press conference will be held jointly by Orexo and Biolipox at 10 a.m. today, Monday, 15 October 2007. Location: Summit, Grev Turegatan 30, Stockholm. wkr0001.pdf Regulatory Pressrelease Orexo adds two new projects to its development pipeline - abuse proof opioid and a new quick acting treatment for moderate to severe acute pain 3 October 2007 Orexo adds two new projects to its product and technology development portfolio, which will significantly enhance its presence within the therapeutic area of pain management. wkr0025.pdf Regulatory Pressrelease Orexo shows positive results in completed comparative Phase III profile study of the Sublinox™ sleep aid involving insomnia patients 1 October 2007 Orexo has completed a pharmocological profile study for Sublinox™ (OX22) – for treatment of temporary sleeping disturbances. The study shows that Sublinox™ (OX22) acts 30 percent faster than Ambien® as a sleep aid for patients suffering from sleep disturbances. The study also shows that patients remain asleep throughout the night and strengthens existing documentation that Sublinox™ (OX22) represents a safe and effective treatment for temporary insomnia. wkr0028.pdf Regulatory Pressrelease Orexo’s Rapinyl™ nearing regulatory decision in Europe 28 September 2007 Orexo´s European licensing partner ProStrakan Group plc, for the cancer breakthrough pain product Rapinyl™ on the European market, today announced that Rapinyl™ will be referred for review by the Committee for Medicinal Products for Human Use (CHMP) of the EMEA. Of the 25 member states involved in the EU Decentralised Procedure (DCP) for Rapinyl™, 21 consider this product to be approvable. wkr0043.pdf Regulatory Pressrelease Orexo´s treatment for incontinence/nocturia entering Phase I 29 August 2007 FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) +44 (0)1737 821891 / 892 (F) +44 (0)1737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo’s product for nocturia and on demand treatment of urinary incontinence, OX 19 (sublingual desmopressin) has started phase 1 trials. Orexo has developed several formulations and is now proceeding to investigate the lead formulation. The bioavailability trial, which is taking place in Sweden, is expected to be completed by the end of this year. OX 19 exploits Orexo’s novel sublingual tablet technology which enables rapid and reliable onset of action. wkr0053.pdf Regulatory Pressrelease Orexo strengthens its clinical and regulatory team with the appointment of three senior executives 17 August 2007 FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) 01737 821891 / 892 (F) 01737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo (OMX Midcap:ORX.) has strengthened its clinical and regulatory team with the appointment of three senior executives - Mats Eriksson PhD, VP Research and Clinical Development and Medical Director for Orexo, Christina Ståhl MSc. Pharm, Vice President Regulatory Affairs, and Anne Marie Ciupitu MSc, PhD, Director QA/QC. wkr0001.pdf Regulatory Interim Report Interim Report January - June 2007 14 August 2007 wkr0085.pdf Regulatory Pressrelease Orexo establishes sales force in Nordic markets, by entering into a joint venture with ProStrakan 1 August 2007 FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) 01737 821891 / 892 (F) 01737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo (OMX Midcap:ORX.) has embarked on the next phase of its growth strategy by entering into a joint venture agreement with ProStrakan in the Nordic territories. Together Orexo and ProStrakan are establishing a sales operation, which will be owned equally. The new entity will have Nordic sales rights for both Orexo’s and ProStrakan’s portfolio which will include currently marketed and future products, Tostrex®, Rectogesic® and Droperidol®, followed by Rapinyl™, Orexo’s patented product for the treatment of cancer break through pain for which ProStrakan holds the European distribution rights, and ProStrakan’s product Sancuso® for the prevention of chemotherapy-induced nausea and vomiting, both currently undergoing the European regulatory process. wkr0011.pdf Regulatory Interim Report Interim Report, January - March 2007 9 May 2007 wkr0010.pdf Regulatory Pressrelease Orexo receives European patent approval for OX 17 9 May 2007 Orexo has been informed by the European patent authority that Orexo’s patent for the combination concept for the treatment of GERD – gastroesophageal reflux disease – has been granted and will be published on May 30, 2007. The patent is a formulation patent protecting combinations of H2-receptor blockers and proton pump inhibitors (PPI). The patent has previously been approved in China, Australia and New Zealand, and patent is pending in the North-American market. wkr0001.pdf Regulatory Pressrelease Report from Orexo AB’s Annual General Meeting, 23 April 2007 24 April 2007 wkr0010.pdf Regulatory Pressrelease Notice of Annual General Meeting in Orexo AB 22 March 2007 wkr0010.pdf Regulatory Annual Financial Statement Year-end Report, January - December 2006 20 February 2007 wkr0019.pdf Regulatory Pressrelease Orexo AB – Financial calendar 2007 18 January 2007 Orexo AB (publ) today announced the following preliminary dates for the release of its quarterly reports and the Annual General Meeting in 2007: wkr0001.pdf Regulatory Pressrelease Orexo submits registration application (IND) to FDA to complete the Phase III clinical study for the insomnia product Sublinox™ (OX 22) 20 December 2006 Orexo AB has submitted a registration application to FDA to complete Orexo’s clinical Phase III program for the insomnia product Sublinox™ (OX 22) - Orexo´s patented product for treatment of temporary sleeping disturbances. The studies are expected to be completed in the second half of 2007. A registration application for the US and EU markets are estimated to be submitted at the end of 2007. wkr0010.pdf Regulatory Pressrelease Orexo announces another agreement for its pain product Rapinyl™ 19 December 2006 Orexo AB and the Hungarian pharmaceutical company Gedeon Richter Ltd. today announced that they have entered into a distribution agreement under which Gedeon Richter receives exclusive rights to market and sell Rapinyl™ – Orexo´s patented product for management of breakthrough cancer pain – in CIS, Bulgaria and Rumania. This is Orexo’s first distribution agreement for Rapinyl™. The marketing rights have previously been out-licensed in the U.S, EU and Japan. wkr0010.pdf Regulatory Pressrelease Orexo strengthens its organization for continued and expanded development of its portfolio – Christina Rångemark Åkerman appointed Head of Technology- and Product Development 5 December 2006 Orexo AB has appointed Christina Rångemark Åkerman as Senior Vice President and Head of Technology and Product Development. She assumes her position on February 1, 2007. She will be responsible for project management, R&D, clinical development and regulatory affairs. The recruitment is a step to further strengthen Orexo’s organization as the company prepares for increasing its investments in developing new products, and simultaneously, preparing some of its existing products for entering clinical phase III-trials. wkr0001.pdf Regulatory Pressrelease Nomination Committee for Orexo´s Annual General Meeting 2007 9 November 2006 At Orexo AB;s Annual General Meeting on 27 April 2006, it was resolved that the Chairman of the Board of Directors shall, not later than six months before the Annual General Meeting, announce a Nomination Committee comprising one representative for each of the three largest shareholders in terms of the number of votes. wkr0010.pdf Regulatory Pressrelease Orexo builds a platform for new, innovative drugs by developing a unique drug delivery technology 24 October 2006 The pharmaceutical company Orexo has initiated a collaboration with the medical technology company Doxa. Orexo and Doxa are to develop new, innovative pharmaceuticals based on a unique drug delivery technology, which will be designed for slow and controlled release of the active ingredient. The initial and primary objective is to develop a new, improved pharmaceutical product for pain treatment. wkr0019.pdf Regulatory Pressrelease Orexo receives SEK 38 M from Endo Pharmaceuticals Inc. 23 October 2006 Orexo AB is receiving license revenue amounting to USD 5.2 M (slightly more than SEK 38 M) from Endo Pharmaceuticals Inc. pertaining to Rapinyl™. Endo Pharmaceuticals has exclusive rights to the further development and marketing of Rapinyl™ on the North American market and is currently conducting a Phase III program to support registration in the US for treatment of breakthrough pain in opiod-tolerant cancer patients. To date, Orexo has received license revenues from Endo Pharmaceuticals Inc. totaling about SEK 161 M. wkr0019.pdf Regulatory Interim Report Interim Report, January – September 2006 18 October 2006 wkr0019.pdf Regulatory Pressrelease Orexo receives 2 million EURO in milestone payment 4 September 2006 wkr0010.pdf Regulatory Pressrelease Orexo’s licensing partner submits registration file for the pain product Rapinyl™ 4 September 2006 wkr0010.pdf Regulatory Interim Report Interim Report, January–June 2006 21 August 2006 wkr0010.pdf Regulatory Pressrelease Orexo presents positive study results for Sublinox™ (OX 22) at APSS (Associated Professional Sleep Societies) 26 June 2006 wkr0001.pdf Regulatory Pressrelease Orexo to complete acquisition 9 June 2006 wkr0001.pdf Regulatory Pressrelease Unique clinical profile for Orexo’s product “OX 17” confirmed 22 May 2006 wkr0010.pdf Regulatory Interim Report Interim Report, January-March 2006 12 May 2006 wkr0019.pdf Regulatory Pressrelease Report from the Annual General Meeting in Orexo held on April 27, 2006 27 April 2006 wkr0010.pdf Regulatory Pressrelease Orexo acquires Noster System – strengthens its position in stomach-ulcer diagnostics 27 April 2006 wkr0019.pdf Regulatory Annual Financial Statement Year-end Report, January - December 2005 23 February 2006 wkr0010.pdf Regulatory Pressrelease Orexo AB – Financial calendar 2006 10 January 2006 wkr0001.pdf Regulatory Pressrelease Orexo announces a licensing agreement for its pain product Rapinyl™ (OX 20) for the European market 21 December 2005 wkr0010.pdf Regulatory Pressrelease Orexo AB IPO - Notice of Over-Allotment Option Exercise 8 December 2005 wkr0001.pdf Regulatory Interim Report Interim Report, January - September 2005 11 October 2005 wkr0001.pdf Regulatory Pressrelease Development milestone payment to Orexo after completed clinical study 3 October 2005 Orexo AB has met the requirements for its first $6.5 million development milestone payment from Endo Pharmaceuticals Inc., following the completion of a clinical trial of Rapinyl™ (OX 20) with positive outcome. In this trial, the dose range to be used in the next stage of development was established. Orexo’s patented product Rapinyl™ (OX 20) is being studied for the management of breakthrough cancer pain . The two companies entered into a licensing agreement August 2004, which gives Endo Pharmaceuticals exclusive rights to develop and market Rapinyl™ (OX 20) for the North American market. wkr0001.pdf Regulatory Pressrelease Correction from Orexo - Rättelse från Orexo 27 September 2005 Regulatory Pressrelease Correction from Orexo - Rättelse från Orexo 27 September 2005 Regulatory Interim Report Interim Report, January - June 2005 19 September 2005 wkr0001.pdf Regulatory Pressrelease Press release - Orexo AB's Extraordinary General Meeting Sept 16 19 September 2005 wkr0010.pdf Regulatory Pressrelease Press release - Orexo AB’s Extraordinary General Meeting Sept 16 19 September 2005 wkr0001.pdf Regulatory Pressrelease Orexo recruits and reorganizes for continued rapid expansion 26 August 2005 Claes Wenthzel has been appointed Executive Vice President and Chief Financial Officer (CFO) at Orexo AB, with overall responsibility for the company’s financial and administrative functions. Thomas Lundqvist, co-founder of Orexo, moves from his role as Executive Vice President and Head of Research & Development to become Executive Vice President & Chief Scientific Officer (CSO), with overall responsibility for the company’s scientific operations. Concurrently, Nils-Otto Ahnfelt, formerly Project Director, assumes the position Vice President Research & Development. wkr0001.pdf Regulatory Pressrelease Orexo sells its peptide technology 16 June 2005 Orexo AB has sold the rights for its cell-penetrating peptide technology, CPP – purchase price 9,5 MSEK. wkr0001.pdf Regulatory Interim Report Interim report, January–March 2005 19 May 2005 wkr0001.pdf Regulatory Pressrelease Professor John Sjögren new board member of Orexo AB 4 May 2005 At Orexo’s Annual General Meeting on April 20, 2005, Professor John Sjögren was elected new member of the Board of Directors. John Sjögren has many years of experience in drug development within Astra Hässle and unique knowledge in pharmaceutics – the science of the delivery of pharmaceutical substances for the most effective therapeutic impact. wkr0001.pdf Regulatory Pressrelease Thomas Leoo appointed new VP/Medical Director at Orexo AB 14 April 2005 Dr. Thomas Leoo has been appointed new Vice President & Medical Director at Orexo AB, based in Uppsala, Sweden. With his broad experience from clinical development, he adds important expertise to the company’s continued expansion. wkr0001.pdf Regulatory Pressrelease Orexo boosts efforts on its diagnostic pharmaceutical – establishes subsidiary centered on Diabact® UBT 21 March 2005 The Swedish drug-delivery company Orexo, is increasing its efforts on its first commercialized product Diabact®UBT by establishing a subsidiary based on the product. Lena Söderström, most recently Director Business Development at Fresenius Kabi AB, will be appointed as Managing Director of the subsidiary. wkr0010.pdf Regulatory Pressrelease Orexo completes clinical study with positive results 28 February 2005 Orexo has completed an efficacy study for OX 22, with positive results. OX 22 is a pharmaceutical product for the treatment of temporary insomnia, a product which is considered to have substantial medical and commercial potential. Negotiation with potential partners for commercialisation of OX 22 has been initiated. wkr0010.pdf Regulatory Pressrelease Orexo accelerates its portfolio development – Dr. Nils-Otto Ahnfelt assumes position as Project Director 28 January 2005 Uppsala-based biotechnology company Orexo is further strengthening its organization through the recruitment of Dr. Nils-Otto Ahnfelt as Project Director, with the task of driving development of the company’s product portfolio on a project basis. Dr. Ahnfelt will also be a member of Orexo’s executive management team. Nils-Otto Ahnfelt has more than 20 years of industry experience, mainly from Pharmacia, and joins Orexo from Doxa AB, where he was head of the company’s Research and Development . wkr0001.pdf Regulatory Pressrelease Orexo expands further – broadens operations and recruits new employees 13 January 2005 Sweden-based biotechnology company Orexo, continues to expand. During the first half of 2005, a new, directly owned analytical laboratory will become operational, strengthening the company’s ability to accelerate the development of its´ product portfolio. Furthermore, additional expertise has been recruited to facilitate this development. wkr0010.pdf Regulatory Pressrelease Orexo AB announces a major pharmaceutical deal for Rapinyl(TM) in North America 19 August 2004 wkr0001.pdf Regulatory Pressrelease Orexo AB announces a major pharmaceutical deal for Rapinyl® in North America 19 August 2004 wkr0010.pdf Regulatory Pressrelease Catella Capital new shareholder in Orexo Pharmaceuticals 17 August 2004 wkr0010.pdf Regulatory Pressrelease Catella Capital new shareholder in Orexo Pharmaceuticals 17 August 2004 wkr0001.pdf Regulatory Pressrelease Monica Caneman new board member of Orexo AB 26 July 2004 Orexo AB in Uppsala announces the election of Monica Caneman as new member of its Board of Directors. Monica Caneman previously worked for SEB, where she was employed for more than 20 years, the last four as Deputy CEO. wkr0001.pdf Regulatory Pressrelease Monica Caneman new board member of Orexo AB 26 July 2004 wkr0001.pdf Regulatory Pressrelease Internationally experienced pharmaceuticals executive recruited to Swedish biotech company-Zsolt Lavotha new president o 14 April 2004 wkr0001.pdf Regulatory Pressrelease Orexo Pharmaceuticals patent for rapid delivery issued in the EU 24 March 2004 wkr0001.pdf Regulatory Pressrelease Orexo Pharmaceuticals elects Håkan Åström as new Chairman of the Board 15 December 2003 wkr0001.pdf Regulatory Pressrelease Orexo Pharmaceuticals acquires CePeP 29 August 2003 wkr0001.pdf Regulatory Pressrelease Diabact licenses rights to Kyowa Hakko for a new cancer pain product 14 February 2003 wkr0001.pdf Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy